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Abstract Vanilloid receptors (VRs) play a fundamental role in
the transduction of peripheral tissue injury and/or inflammation
responses. Molecules that antagonize VR channel activity may
act as selective and potent analgesics. We report that synthetic
arginine-rich hexapeptides block heterologously expressed VR-1
channels with submicromolar efficacy in a weak voltage-
dependent manner, consistent with a binding site located near/
at the entryway of the aqueous pore. Dynorphins, natural
arginine-rich peptides, also blocked VR-1 activity with micro-
molar affinity. Notably, synthetic and natural arginine-rich
peptides attenuated the ocular irritation produced by topical
capsaicin application onto the eyes of experimental animals.
Taken together, our results imply that arginine-rich peptides are
VR-1 channel blockers with analgesic activity. These findings
may expand the development of novel analgesics by targeting
receptor sites distinct from the capsaicin binding site. ß 2000
Federation of European Biochemical Societies. Published by
Elsevier Science B.V. All rights reserved.
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1. Introduction
Capsaicin, the pungent ingredient of red peppers, exerts its
irritant action by exciting sensory nerve endings that signal
tissue injury (nociceptors), and whose activation leads ulti-
mately to a conscious sensation of pain [1^3]. Because excita-
tory e¡ects of capsaicin are followed by long-lasting inactiva-
tion, capsaicin is also used as an analgesic molecule for the
treatment of diverse pain and in£ammatory conditions [4^6].
In recent years the understanding of the molecular mecha-
nisms underlying capsaicin nociceptive and analgesic activity
has advanced considerably with the cloning of a capsaicin-
operated neuronal receptor referred to as the vanilloid recep-
tor subunit 1 (VR-1) [7,8]. VR-1 is a non-selective cation
channel with high Ca2 permeability. Activation of VR-1 by
capsaicin leads to an increase in intracellular Ca2 that results
in a change of the metabolic state in sensory neurons [7,9].
Ca2 permeability appears also to be involved in capsaicin-
induced desensitization of VR-1 channels, the physiological
property underlying the analgesic activity exhibited by capsai-
cin [3,9]. By contrast, high doses of the vanilloid produce a
prolonged activation of VR-1 channels leading to neurodegen-
eration [3,10]. In addition to their sensitivity to capsaicin, VR-
1 channels are also operated by thermal stimuli, by in£amma-
tory mediators and by protons [3,7^9].
The central role played by VR-1 channels in the transduc-
tion of chemical and thermal stimuli makes this receptor a
molecular target for drug intervention [3,6]. This notion has
been substantiated by the pain perception impairment exhib-
ited by mice lacking VR-1 channels [11,12]. Despite the wealth
of information accrued in recent years on VR-1 function, the
number of available compounds that modulate its activity is
still quite limited [6]. Structure^activity studies have focused
on synthesizing competitive capsaicin antagonists such as cap-
sazepine and analogs [5,13]. Among the non-competitive an-
tagonist family, only ruthenium red is accepted as a VR-1
blocker [14]. Here, we report that arginine-rich hexapeptides
are potent blockers of the recombinant homomeric VR-1
channel expressed in Xenopus oocytes. Synthetic hexapeptides
blocked VR-1 channels with submicromolar e⁄cacy in a mod-
estly voltage-dependent manner. We also found that naturally
occurring, arginine-containing peptides such as dynorphins
block VR-1 channels at micromolar concentrations. Our ¢nd-
ings suggest that arginine-rich peptides act as VR-1 channel
blockers. Notably, synthetic hexapeptides displayed analgesic
activity as evidenced by the attenuation of the irritant activity
induced by topical application of capsaicin onto the eyes of
experimental animals. Hence, VR-1 arginine-rich peptide
channel blockers may constitute a novel family of analgesic
molecules.
2. Materials and methods
2.1. Peptide synthesis and puri¢cation
Arginine-rich hexapeptides (RRRRWW-NH2, RRWWIR-NH2,
and RYYRRW-NH2 ; capital letters denote L-amino acids) were man-
ually synthesized by the solid-phase method using the base-labile
9-£uorenylmethoxycarbonyl (Fmoc) group for protection of the ami-
no function [15]. Peptides were assembled on a TentaGel S RAM
resin (0.24 mmol/g; Rapp Polymere, Germany) to produce a peptide
with a C-terminal amide moiety using diisopropylcarbodiimide (DIC)/
hydroxybenzotriazole (HOBT)-mediated couplings (1 eq. each amino
acid of HOBT and 2 eq. DIC). The Fmoc groups were cleaved by 20%
piperidine in dimethylformamide for 30 min. Each deprotection or
coupling step was veri¢ed by the ninhydrin test. Peptides were cleaved
from the resin with 70% tri£uoroacetic acid/20% dichloromethane/5%
water/2.5% ethanodithiol/2.5% chlorotriisobutylsilane for 4 h at room
temperature. Fully deprotected peptides were precipitated in t-butyl-
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methyl ether, centrifuged, dissolved in acetic acid and freeze-dried.
Peptides were puri¢ed by HPLC on a Lichrosphere 100 RP 18
(5 Wm) column (Waters). Peptide identity was con¢rmed by MAL-
DI-TOF spectrometry.
2.2. cRNA preparation and microinjection into Xenopus oocytes
All the procedures have been described in detail elsewhere [16,17]
and are followed accordingly, unless otherwise indicated. Brie£y,
capped cRNA for the VR-1 subunit was synthesized from linearized
cDNA (kindly provided by Dr. David Julius) using the mMESSAGE
mMACHINE1 from Ambion (Texas). cRNA (0.2 mg/ml) was micro-
injected (50 nl) into defolliculated oocytes (stage V and VI) as de-
scribed. Oocytes were functionally assayed 2^4 days after cRNA in-
jection.
2.3. Electrophysiological characterization of VR-1 channels expressed
in Xenopus oocytes
Whole-cell currents were recorded with a conventional two-micro-
electrode voltage-clamp ampli¢er at 20‡C [16,17]. All electrophysio-
logical studies were performed in Mg2-Ringer’s solution (in mM:
10 HEPES pH 7.4, 115 NaCl, 2.8 KCl, 0.1 BaCl2, 2.0 MgCl2). Ho-
momeric VR-1 channels were activated by application of 20 WM cap-
saicin in the absence or presence of increasing concentrations of chan-
nel blockers at a holding potential (Vh) of 380 mV. Responses were
normalized with respect to that evoked in the absence of channel







where IC50 denotes the channel blocker concentration that inhibits
half of the response obtained in its absence (Imax) and n denotes the
Hill coe⁄cient which is an estimate of the number of drug binding
sites [19]. Experimental data were ¢tted to the Hill equation with a
non-linear least-squares regression algorithm using MicroCal ORI-
GIN version 5.0 (Microcal, Amherst).
I^V characteristics were recorded using a ramp protocol [17]. Oo-
cytes were depolarized from 380 mV to 20 mV in 5 s (20 mV/s). Leak
currents were measured in the absence of agonist in the external bath
medium and subtracted from the ionic current recorded in the pres-
ence of the ligand. Voltage dependence of channel blockade was
studied as described [20].
2.4. Evaluation of in vivo analgesic activity
The topical analgesic activity of VR-1 channel blockers was eval-
uated in OF-1 mice by comparing the number of scratching move-
ments evoked by topical ocular application of 2.5 Wl of a 0.01% of a
capsaicin solution (333 WM), before and after treatment with peptides
or their vehicle [21,22]. The number of capsaicin-induced scratching
movements was counted during 1 min immediately after application
of the drug to one eye. Thereafter, the eye was extensively washed
with saline solution. After a 15 min period, a 2.5 Wl drop of either VR-
1 channel blocker at the speci¢ed concentrations or saline solution
was applied. Five minutes afterwards, a mixture of capsaicin and
channel blocker (or, alternatively, saline solution) was applied to the
same eye and the number of scratching movements during 1 min after
drug instillation was counted. This protocol was performed in both
eyes. The normalized number of scratching movements was de¢ned as
follows:
Normalized scratching movements  Sb3Sa
Sc3Sa
where Sb denotes the number of scratching movements in the presence
of channels blocker or saline upon the second capsaicin application,
Sc is the number of scratching movements of the ¢rst capsaicin ap-
plication, and Sa represents the number of scratching movements of
the second capsaicin instillation upon the application of the local
anesthetic 40% oxobuprocaine/10% tetracaine. Capsaicin was dis-
solved in 15% ethanol and 8.5% Tween-80 (33 mM) and then diluted
with saline solution to the ¢nal concentration (0.33 mM). Capsazepine
was prepared at 1.0 mM in 5% dimethyl sulfoxide. Peptides were
dissolved in saline solution. Results are given as mean þ S.E.M.,
Fig. 1. Arginine-rich hexapeptides inhibit VR-1 channel activity. Block of capsaicin-evoked ionic currents from recombinant VR-1 channels by
RRRRWW-NH2 (A) and RRWWIR-NH2 (B). The pulse protocols are indicated above the current traces. The length of the solid lines indi-
cates perfusion duration. VR-1 channels were activated by 20 WM capsaicin and recorded at a holding potential (Vh) of 380 mV. Downward
de£ection indicates inward current. Dose^response curves for (C) RRRRWW-NH2 and (D) RRWWIR-NH2 inhibition of capsaicin-activated
ionic currents of VR-1 channels expressed in Xenopus oocytes. Responses were normalized with respect to that in the absence of hexapeptides.
Ionic currents were elicited by 20 WM capsaicin at Vh =380 mV. Solid lines depict the theoretical ¢ts to a Michaelis^Menten binding isotherm.
Each point represents the mean þ S.E.M. with N (number of oocytes)v 4.
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with N (number of animals) v10. Treatment administration (channel
blockers and saline) was randomized. Scratching movements were
evaluated blindly.
3. Results
3.1. Arginine-rich hexapeptides block VR-1 channel activity
with high e⁄cacy and potency
Homomeric VR-1 permeation properties closely resemble
those described for the N-methyl-D-aspartic acid receptor
(NMDAR), namely they are non-selective cation channels
with remarkable permeability to Ca2 and high sensitivity to
Ca2 blockade [9]. These properties suggest the presence of a
high a⁄nity Ca2 binding site in the permeation pathway akin
to that present in NMDARs [23,24]. The NMDAR Ca2
binding site is a target site for arginine-rich hexapeptides,
which block its channel activity with high e⁄cacy and potency
[25]. Hence, we reasoned that VR-1 receptors may also be
modulated by these molecules. To test this hypothesis we se-
lected the hexapeptides: RRRRWW-NH2 which shows high
e⁄cacy blocking NMDARs, RRWWIR-NH2 that display
lower blocking e⁄cacy and selectivity, and RYYRRW-NH2
which shows the lowest a⁄nity for NMDARs.
As illustrated in Fig. 1A, perfusion of voltage-clamped oo-
cytes expressing VR-1 channels with 20 WM capsaicin elicited
a slowly activating inward current that was reduced byV50%
upon addition of 0.1 WM RRRRWW-NH2, and by V80%
when oocytes were exposed to 1.0 WM hexapeptide. Similar
blocking activity was obtained for RRWWIR-NH2, although
this hexapeptide appears less potent (Fig. 1B). The inhibitory
activity displayed by both arginine-rich hexapeptides was re-
versible, as evidenced by the recovery of capsaicin-evoked
ionic currents after antagonist wash-out (data not shown).
The e⁄cacy and potency of VR-1 blockade by these hexapep-
tides were obtained from the dose^response relationships (Fig.
1C,D). For RRRRWW-NH2, the IC50 was 0.10 þ 0.06 WM
and n = 0.76 þ 0.10, for RRWWIR-NH2 it was 0.40 þ 0.10
WM and n = 0.80 þ 0.12, and for RYYRRW-NH2 it was
2 þ 1 WM and n = 0.85 þ 0.13, substantiating the higher block-
ade activity of the former hexapeptide. The Hill coe⁄cient of
V1.0 is consistent with the occurrence of a single binding site.
Peptides appear to be non-competitive antagonists of homo-
meric VR-1 channels, as evidenced by the virtually identical
capsaicin EC50 (concentration of capsaicin to activate half the
maximal response) in the absence (0.4 þ 0.08 WM, N = 4) and
in the presence of 0.1 WM RRRRWW-NH2 (0.3 þ 0.1 WM,
N = 3) or 0.5 WM RRWWIR-NH2 (0.6 þ 0.15 WM, N = 3).
Taken together, these results indicate that arginine-rich hex-
apeptides are potent blockers of VR-1 channels and suggest
the presence of a negatively charged drug binding site on these
receptors similar to that reported for NMDARs, Ca2 chan-
nels, and cyclic nucleotide-gated channels [24,26,27].
3.2. Arginine-rich hexapeptides are channel blockers of
VR-1 receptors
To investigate the mechanism underlying the blockade ac-
tivity of arginine-rich hexapeptides and to locate the binding
site, we studied the voltage dependence of VR-1 inhibition
[28]. I^V relationships from 380 mV to 20 mV were obtained
using ramp protocols (Fig. 2). VR-1 channel activity displayed
a linear I^V relation between 340 mV and 20 mV that
changed to inward recti¢cation at voltages below 350 mV.
The reversal potential for VR-1 channels was 1.3 þ 2.2 mV
(mean þ S.E.M., n = 4) in Mg2-Ringer which is in good
agreement with previous reports [7]. Arginine-rich hexapepti-
des blocked VR-1 channel activity primarily at negative mem-
brane potentials without signi¢cantly changing the appear-
ance of the I^V curve nor the current reversal potentials
Fig. 2. Voltage-dependent blockade by RRRRWW-NH2 (A) and RRWWIR-NH2 (B) of recombinant VR-1 channels expressed in amphibian
oocytes. Current^voltage characteristics of ionic currents evoked by 20 WM capsaicin in the absence (control) or presence (RRRRWW-NH2 or
RRWWIR-NH2) of hexapeptides at the speci¢ed concentrations. Each trace is representative of at least three oocytes. Oocytes were held at
380 mV and depolarized to 20 mV in 5 s (20 mV/s) using a ramp protocol. Leak currents were obtained in the absence of capsaicin and sub-
tracted from the agonist-evoked ionic currents. Inset represents the fraction of unblocked response (Iblocked/Icontrol) as a function of the applied
voltage. Solid lines depict the best ¢t to a model that considers the existence of a single binding site within the pore and a negligible multiple
ion occupancy of this site [29]. The values obtained for RRRRWW-NH2 were N= 0.20 and IC50 (0 mV) = 0.46 WM, and for RRWWIR-NH2
were N= 0.16 and IC50 (0 mV) = 0.65 WM.
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(3.0 þ 3.1 mV for RRRRWW-NH2 and 4.0 þ 2.6 mV for
RRWWIR-NH2). These results suggest that VR-1 blockade
by arginine-rich hexapeptides is weakly voltage-dependent,
and imply that the peptide binding sites sense the pore electro-
static ¢eld. To further substantiate this observation, we ob-
tained the fraction of unblocked response (Iblocker/Icontrol) as a
function of the membrane potential (Fig. 2, insets). The frac-
tion of unblocked response^voltage relationship is related to
the location of the blocker binding site within the membrane
electrostatic ¢eld [20,28^31]. For both peptides, experimental
data exhibited a weak dependence on the applied membrane
voltage, consistent with a rather external location of the drug
binding site. Indeed, considering the occurrence of a single
binding site within the pore electric ¢eld and a negligible
multiple ion occupancy of this site [29], the inferred electrical
distance of the peptide binding site from the mouth of the
channel, N, was 0.2 for RRRRWW-NH2 and 0.16 for
RRWWIR-NH2 (Fig. 2, insets). This observation implies
that the drug binding site is located near or at the entryway
of the aqueous pore, and suggests that arginine-rich peptides
act as VR-1 channel blockers.
3.3. Naturally occurring arginine-rich peptides block VR-1
channel activity
A question that arises is: do naturally occurring, arginine-
rich peptides modulate VR-1 channel activity? Dynorphins
are neuropeptides containing a signi¢cant number of basic
residues in their amino acid sequence suggesting that they
may modulate VR-1 channel activity. As displayed in Fig.
3A, dynorphin A ([1^17]: YGGFLRRIRPKLKWDNQ-
NH2) reversibly blocked capsaicin-activated ionic current in
oocytes expressing recombinant VR-1 receptors. Similarly,
two shorter versions of dynorphin A, dynorphin [2^13]
(GGFLRRIRPKLK-NH2) and dynorphin [1^10] (YGGFLR-
RIRP-NH2), comprising the core structure of the longer se-
quence, blocked VR-1 channel activity with similar e⁄cacy,
dynorphin [1^10] being the least potent. Notice that dynor-
phin blockade was readily washable (Fig. 3A,B). The blocking
activity of dynorphin peptides was comparable to that char-
acteristic of arginine-rich hexapeptides, although they dis-
played lower blockade e⁄cacy (Fig. 3C). The estimated IC50
was 3 WM for dynorphin A, 5 WM for dynorphin [2^13] and
10 WM for dynorphin [1^10].
Dynorphins inhibited VR-1 channel activity in a voltage-
dependent manner, showing higher blockade e⁄cacy at neg-
ative membrane potentials than at depolarizing voltages (Fig.
3D). As for synthetic hexapeptides, the extent of voltage de-
pendence was weak, compatible with a location of their bind-
ing site close to or at the vestibule of the channel pore. This
¢nding, in conjunction with the positive charge present in
these peptides, suggests that dynorphins may recognize the
same receptor binding site as arginine-rich hexapeptides.
This notion was further supported by the ¢nding that the
IC50 value of RRRRWW-NH2 was increased to 3 þ 1 WM
(N = 3) and of RRWWIR-NH2 was shifted to 6 þ 1 WM
(N = 3) in the presence of 1 WM of dynorphin A.
3.4. Arginine-rich peptides display analgesic activity
VR-1 channels appear involved in the transduction of
chemical and thermal nociception. Thus channel blockers of
Fig. 3. The naturally occurring, arginine-rich dynorphin peptides block VR-1 channel activity. Block of capsaicin-evoked ionic currents from re-
combinant VR-1 channels by dynorphin A (A) and dynorphin [2^13] (B). The pulse protocols are indicated above the current traces. The
length of the solid lines indicates perfusion duration. C: Comparative blockade activity exerted by 5 WM dynorphin peptides. Responses were
normalized with respect to that in the absence of peptides. VR-1 channels were activated by 20 WM capsaicin and recorded at a holding poten-
tial (Vh) of 380 mV. Downward de£ection indicates inward current. Each point represents the mean þ S.E.M. with Nv3. D: Current^voltage
characteristics of ionic currents evoked by 20 WM capsaicin in the absence (control) or presence (dynorphin A) of 5 WM dynorphin A. Other
conditions as described in Fig. 2.
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these ionotropic channels may exhibit analgesic activity. We
approached this issue and measured whether or not arginine-
rich peptides ameliorated the irritant activity produced by
topical application of capsaicin to the eyes of mice [21,22].
The cornea, conjunctiva, and anterior uvea are densely inner-
vated by polymodal nociceptive ¢bers that are directly excited
by capsaicin [32^34]. When applied topically to the eye of
experimental animals, the vanilloid evokes immediate pain
as evidenced by the increment in the number of scratching
movements of the treated eye (29.5 þ 3.1 scratching move-
ments). Intriguingly, the ocular discomfort produced by cap-
saicin application was not signi¢cantly reduced by application
of 1.0 mM of the competitive capsaicin antagonist capsaze-
pine (26.5 þ 3.5 scratching movements), substantiating the
proposed existence of vanilloid receptors insensitive to this
drug [3,33,35,36]. Treatment with 10 mM of the L-amino
acid hexapeptides RRRRWW-NH2 and RRWWIR-NH2 did
not signi¢cantly reduce the number of vanilloid-evoked
scratching movements (data not shown). By contrast, capsai-
cin-induced ocular irritation was decreased by 40% after ap-
plication of 10 mM of the proteolysis-resistant all-D-amino
acid hexapeptide rrrrww-NH2 (counterpart of L-amino acid
peptide RRRRWW-NH2), and by 15% upon the treatment
with the all-D-amino acid peptide rrwwir-NH2 (Fig. 4). This
analgesic activity was comparable, albeit lower, to that dis-
played by dynorphin A (v50% attenuation at 10 mM). The
observed attenuation of capsaicin-induced ocular irritation
was not due to VR-1 desensitization since instillation of a
second capsaicin pulse did not alter the number of scratching
movements (29.0 þ 3.5). Moreover, the in vivo analgesic activ-
ity of rrrrww-NH2 was concentration-dependent as evidenced
by its disappearance at lower peptide concentrations
(27.5 þ 2.3 scratching movements at 1 mM). Accordingly, ar-
ginine-rich peptides appear to be VR-1 channel blockers with
analgesic activity.
4. Discussion
We have found that small positively charged peptides are
blockers of VR-1 channels. These peptides blocked capsaicin-
operated ionic currents with micromolar e⁄cacy in a weakly
voltage-dependent manner. The blockade activity of arginine-
rich peptides resembles that reported for ruthenium red, a
widely accepted non-competitive antagonist of VR-1 channels
[14]. The inhibitory activity of arginine peptides exhibit a Hill
coe⁄cient of V1, suggesting the presence of a single binding
site on the receptor. The weakly voltage-dependent blockade
exerted by synthetic peptides and dynorphins suggests that a
small fraction of the electrostatic ¢eld (N) is sensed by their
blocking site [28]. Indeed, the estimated electrical distance,
N9 0.2, indicates that arginine-rich peptides traverse partway
through the membrane electrostatic ¢eld to reach its binding
site [20,28,29]. Accordingly, arginine-rich peptides appear to
be non-competitive antagonists of VR-1 channels that act as
channel blockers. Their binding site seems to be located near
or at the entryway of the permeation pathway. A question
that ensues is: how might the binding site be structured?
Analysis of amino acid sequence of the P-loop reveals the
presence of four negatively charged residues (E636, D646,
E648, E651) that could structure one or more negatively
charged rings akin to that described for Ca2 channels and
cyclic nucleotide-gated channels [26,27]. Interestingly, D646
and E648 are next to the GMG motif, which is similar to
the highly conserved signature sequence GYG motif of volt-
age-gated potassium-selective channels [37] substantiating the
hypothesis that this residue may be an important molecular
determinant of both blocker sensitivity and ion selectivity.
Accordingly, the molecular composition of the VR-1 P-loop
is compatible with the presence of a binding site for positively
charged molecules. Structure^function studies on VR-1 chan-
Fig. 4. Arginine-rich peptides ameliorate the pungent activity of
capsaicin. A: Experimental protocol to evaluate the potential in
vivo analgesic activity of VR-1 blockers. 2.5 Wl of 333 WM capsaicin
is topically applied (a) onto the eye of a mouse and the pungent ac-
tivity is evaluated by counting the scratching during the ¢rst minute
after treatment. The eye is washed with 1 ml saline (b) and allowed
to rest for 15 min. Thereafter, 2.5 Wl of saline or blocker is applied
(c). After 5 min incubation to allow blocker di¡usion, capsaicin
alone or mixed with blocker is applied (d) onto the eye, and the
scratching activity is counted during the ¢rst minute after vanilloid
application. B: Comparison of scratching activity evoked by topical
application of capsaicin onto the eyes of animals. Responses were
normalized with respect to the number of scratching movements
counted in the ¢rst application of capsaicin (29.5 þ 3.1), and that
evoked upon treatment with the local anesthetic (10 þ 3) before the
second application of the vanilloid. The scratching movements
counted upon the second addition of capsaicin in the absence (sa-
line) or presence of peptides were: 29 þ 3.5 for saline, 26.5 þ 2.1 for
rrwwir-NH2, 23 þ 1.8 for rrrrww-NH2, and 20 þ 2.1 for dynorphin
A. Peptide concentration was 10 mM. Note that to rule out the sus-
ceptibility of the hexapeptides to proteolytic degradation, we used
the D-amino acid peptide counterparts (denoted with lowercase let-
ters) of RRRRWW-NH2 and RRWWIR-NH2. D-Amino acid pep-
tides blocked VR-1 channels with similar e⁄cacy as their L-amino
acid counterparts (data not shown). Scratching activity was assessed
blindly. Values are given as mean þ S.E.M., with Nv 10 animals.
*P6 0.05, Student’s t-test.
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nels will ultimately identify the molecular determinants that
de¢ne the permeation properties of this novel channel family.
A salient contribution of these results is that channel block-
ers such as arginine-rich peptides display analgesic activity
against capsaicin-evoked ocular irritation. The vanilloid, ap-
plied topically to the eyes of mice, produced immediate signs
of pain that were signi¢cantly attenuated by the topical appli-
cation of the synthetic D-amino acid hexapeptide. The extent
of analgesic activity was comparable to that exhibited by dy-
norphin A, a naturally occurring opioid peptide that activates
U opioid receptors [38,39]. Interestingly, the ¢nding that dy-
norphin A blocks VR-1 channels with micromolar e⁄cacy
implies that its analgesic activity may be partially due by
direct blockade of VR-1 channels. Further experimental
work is required to understand dynorphin A-mediated noci-
ception.
Taken together, our ¢ndings indicate that arginine-rich pep-
tides are channel blockers of VR-1 with in vivo analgesic
activity. These peptides may prove useful as leads for the
development of novel analgesic therapies, and their receptor
binding site may represent a target for discovery of non-pep-
tide drugs.
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